CA3221219A1 - Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid - Google Patents
Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid Download PDFInfo
- Publication number
- CA3221219A1 CA3221219A1 CA3221219A CA3221219A CA3221219A1 CA 3221219 A1 CA3221219 A1 CA 3221219A1 CA 3221219 A CA3221219 A CA 3221219A CA 3221219 A CA3221219 A CA 3221219A CA 3221219 A1 CA3221219 A1 CA 3221219A1
- Authority
- CA
- Canada
- Prior art keywords
- salt
- crystalline form
- xrpd
- diffractometer
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175066P | 2015-06-12 | 2015-06-12 | |
| US62/175,066 | 2015-06-12 | ||
| US201662275655P | 2016-01-06 | 2016-01-06 | |
| US62/275,655 | 2016-01-06 | ||
| CA2988584A CA2988584C (en) | 2015-06-12 | 2016-06-10 | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2988584A Division CA2988584C (en) | 2015-06-12 | 2016-06-10 | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3221219A1 true CA3221219A1 (en) | 2016-12-15 |
Family
ID=57504544
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3221219A Pending CA3221219A1 (en) | 2015-06-12 | 2016-06-10 | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
| CA2988584A Active CA2988584C (en) | 2015-06-12 | 2016-06-10 | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2988584A Active CA2988584C (en) | 2015-06-12 | 2016-06-10 | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10723726B2 (enExample) |
| EP (1) | EP3307722B1 (enExample) |
| JP (1) | JP2018521121A (enExample) |
| KR (1) | KR102663856B1 (enExample) |
| CN (1) | CN107848991B (enExample) |
| AU (2) | AU2016275125A1 (enExample) |
| BR (2) | BR112017026406A2 (enExample) |
| CA (2) | CA3221219A1 (enExample) |
| ES (1) | ES2896674T3 (enExample) |
| IL (1) | IL256237B (enExample) |
| SG (1) | SG10201911442XA (enExample) |
| WO (1) | WO2016201356A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307722B1 (en) | 2015-06-12 | 2021-08-04 | GB006, Inc. | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
| US20200123146A1 (en) * | 2016-12-29 | 2020-04-23 | Gb006, Inc. | Heterocyclic integrin agonists |
| DK3601265T3 (da) * | 2017-03-30 | 2023-09-18 | Merck Patent Gmbh | Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| CA3103522C (en) | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| EP3889136B1 (en) | 2018-11-28 | 2024-12-18 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor |
| WO2020236667A1 (en) * | 2019-05-17 | 2020-11-26 | Gb006, Inc. | Methods of treating cancer |
| WO2021061665A1 (en) * | 2019-09-23 | 2021-04-01 | Gb006, Inc. | Integrin agonist prodrugs |
| WO2021096988A1 (en) | 2019-11-12 | 2021-05-20 | Gb006, Inc. | Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
| WO2023039170A1 (en) * | 2021-09-09 | 2023-03-16 | Musc Foundation For Research Development | Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy |
| WO2024049275A1 (en) * | 2022-09-02 | 2024-03-07 | Rexpharmtech Co., Ltd | Novel benfotiamine choline salt |
| WO2024081449A1 (en) * | 2022-10-14 | 2024-04-18 | Rush University Medical Center | Cd11b agonists for treatment of autoimmune disease |
| CN121197154B (zh) * | 2025-11-13 | 2026-06-23 | 首都医科大学附属北京天坛医院 | Mac-1激动剂在制备治疗和/或缓解脑出血药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002526A1 (en) | 2002-04-03 | 2004-01-01 | Cell Therapeutics, Inc. | Phospholipase D inhibitors and uses thereof |
| EP1654380A4 (en) | 2003-08-14 | 2009-09-09 | Insight Biopharmaceuticals Ltd | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF |
| TW200526638A (en) * | 2003-10-22 | 2005-08-16 | Smithkline Beecham Corp | 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline |
| FI20041129A0 (fi) | 2004-08-30 | 2004-08-30 | Ctt Cancer Targeting Tech Oy | Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi |
| US7718680B2 (en) * | 2004-09-23 | 2010-05-18 | Burnham Institute For Medical Research | Inhibition of lethal factor protease activity from anthrax toxin |
| ITMI20042475A1 (it) * | 2004-12-23 | 2005-03-23 | Cell Therapeutics Europe Srl | Uso di derivati tiazolidinonici come agenti terapeutici |
| WO2008005651A2 (en) * | 2006-06-08 | 2008-01-10 | Decode Chemistry, Inc. | Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis |
| WO2008082537A2 (en) | 2006-12-19 | 2008-07-10 | The General Hospital Corporation | Compounds for modulating integrin cd11b/cd18 |
| WO2008091532A1 (en) * | 2007-01-19 | 2008-07-31 | Panacos Pharmaceuticals, Inc. | Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof |
| US9023876B2 (en) * | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
| CN103159695B (zh) * | 2011-12-08 | 2015-08-12 | 首都师范大学 | 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途 |
| CA2882853C (en) | 2012-04-20 | 2021-11-23 | Vineet Gupta | Compounds and methods for regulating integrins |
| EP3307722B1 (en) | 2015-06-12 | 2021-08-04 | GB006, Inc. | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid |
-
2016
- 2016-06-10 EP EP16808465.5A patent/EP3307722B1/en active Active
- 2016-06-10 BR BR112017026406-4A patent/BR112017026406A2/pt not_active Application Discontinuation
- 2016-06-10 KR KR1020177037752A patent/KR102663856B1/ko active Active
- 2016-06-10 CA CA3221219A patent/CA3221219A1/en active Pending
- 2016-06-10 BR BR122023025347-7A patent/BR122023025347A2/pt not_active Application Discontinuation
- 2016-06-10 CN CN201680041800.5A patent/CN107848991B/zh active Active
- 2016-06-10 AU AU2016275125A patent/AU2016275125A1/en not_active Abandoned
- 2016-06-10 SG SG10201911442XA patent/SG10201911442XA/en unknown
- 2016-06-10 WO PCT/US2016/037067 patent/WO2016201356A1/en not_active Ceased
- 2016-06-10 ES ES16808465T patent/ES2896674T3/es active Active
- 2016-06-10 US US15/735,560 patent/US10723726B2/en active Active
- 2016-06-10 JP JP2018516398A patent/JP2018521121A/ja active Pending
- 2016-06-10 CA CA2988584A patent/CA2988584C/en active Active
-
2017
- 2017-12-11 IL IL256237A patent/IL256237B/en unknown
-
2019
- 2019-11-05 US US16/675,097 patent/US11111239B2/en active Active
-
2020
- 2020-11-16 AU AU2020270457A patent/AU2020270457B2/en active Active
-
2022
- 2022-11-01 US US17/978,848 patent/US12227497B2/en active Active
-
2025
- 2025-01-09 US US19/015,307 patent/US20250353840A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018521121A (ja) | 2018-08-02 |
| AU2016275125A1 (en) | 2018-01-25 |
| US10723726B2 (en) | 2020-07-28 |
| NZ738836A (en) | 2024-03-22 |
| EP3307722B1 (en) | 2021-08-04 |
| BR122023025347A2 (pt) | 2024-01-16 |
| AU2020270457A1 (en) | 2020-12-10 |
| US20180354938A1 (en) | 2018-12-13 |
| US20200317657A1 (en) | 2020-10-08 |
| IL256237B (en) | 2021-12-01 |
| CA2988584A1 (en) | 2016-12-15 |
| US12227497B2 (en) | 2025-02-18 |
| WO2016201356A1 (en) | 2016-12-15 |
| SG10201911442XA (en) | 2020-02-27 |
| KR102663856B1 (ko) | 2024-05-07 |
| CN107848991A (zh) | 2018-03-27 |
| US20250353840A1 (en) | 2025-11-20 |
| EP3307722A1 (en) | 2018-04-18 |
| ES2896674T3 (es) | 2022-02-25 |
| AU2020270457B2 (en) | 2022-10-20 |
| IL256237A (en) | 2018-02-28 |
| CN107848991B (zh) | 2022-01-14 |
| KR20180016443A (ko) | 2018-02-14 |
| US20230227443A1 (en) | 2023-07-20 |
| CA2988584C (en) | 2024-01-23 |
| US11111239B2 (en) | 2021-09-07 |
| BR112017026406A2 (pt) | 2019-04-02 |
| EP3307722A4 (en) | 2018-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020270457B2 (en) | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
| JP7104633B2 (ja) | Ｎｌｒｐ３修飾因子 | |
| AU2019200840C1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| JP7291839B2 (ja) | 固体形態のｃｄｋ４阻害薬 | |
| US12030873B2 (en) | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | |
| JP2023540270A (ja) | 複素環式化合物およびその使用 | |
| TW202317589A (zh) | 作為ｋｒａｓ抑制劑的伸烷基衍生物 | |
| KR20180058741A (ko) | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 | |
| JP2021522249A (ja) | Ｎｌｒｐ３修飾因子 | |
| TW202116778A (zh) | 作為治療劑之細胞毒素之肽結合物 | |
| RS60731B1 (sr) | Čvrsti oblici jedinjenja koje modulira kinaze | |
| CA3147266C (en) | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits | |
| JP2025525376A (ja) | 医学的治療用のサイクリン依存性キナーゼ２阻害剤 | |
| JP2023528868A (ja) | Ｊａｋ１阻害剤の調製プロセス | |
| KR20230058124A (ko) | Mdm2 길항제를 사용하는 암 치료를 위한 생체표지자 | |
| KR20230124648A (ko) | Eif4e 억제제의 고체 형태 | |
| CN111093651A (zh) | Ido抑制剂的无定形和结晶形式 | |
| WO2022026935A1 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| WO2021096988A1 (en) | Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
| RU2786994C2 (ru) | Фармацевтическое соединение | |
| KR20220127848A (ko) | Nlrp3 조정제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231127 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250110 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250422 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250506 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250506 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250506 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250610 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250612 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: OFFER OF REMISSION Effective date: 20260226 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260226 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260330 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260511 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260511 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REMISSION NOT REFUSED Effective date: 20260522 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REMITTANCE REJECTED Effective date: 20260525 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REMISSION NOT REFUSED Effective date: 20260616 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REMITTANCE REJECTED Effective date: 20260616 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REMITTANCE APPROVED Effective date: 20260624 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260720 |